From the Food and Drug Administration.
Henney
J E
JE
Commissioner of Food and Drugs, Rockville, MD 20857, USA.
D016907:Adverse Drug Reaction Reporting Systems; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D005208:Fasciitis / Q000628:therapy*; D005260:Female; D005534:Foot Diseases / Q000628:therapy; D006365:Heel; D006801:Humans; D008297:Male; D008872:Microwaves / Q000009:adverse effects; D010146:Pain / Q000209:etiology; D059408:Pain Management; D011470:Prostatic Hyperplasia / Q000628:therapy*; D017257:Ramipril / Q000627:therapeutic use*; D014464:Ultrasonic Therapy / Q000009:adverse effects; D014465:Ultrasonics; D014481:United States; D014486:United States Food and Drug Administration
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D017257:Ramipril